Discovery and Validation of Novel Methylation Markers in -Associated Gastric Cancer.

Previous studies have shown that abnormal methylation is an early key event in the pathogenesis of most human cancers, contributing to the development of tumors. However, little attention has been given to the potential of DNA methylation patterns as markers for - (-) associated gastric cancer (GC). In this study, an integrated analysis of DNA methylation and gene expression was conducted to identify some potential key epigenetic markers in -associated GC. DNA methylation data of 28 H-positive and 168 H-negative GC samples were compared and analyzed. We also analyzed the gene expression data of 18 H-positive and 145 H-negative GC cases. Finally, the results were verified by and experiments. A total of 5609 differentially methylated regions associated with 2454 differentially methylated genes were identified. A total of 228 differentially expressed genes were identified from the gene expression data of -positive and -negative GC cases. The screened genes were analyzed for functional enrichment. Subsequently, we obtained 28 genes regulated by methylation through a Venn diagram, and we identified five genes (GSTO2, HUS1, INTS1, TMEM184A, and TMEM190) downregulated by hypermethylation. HUS1, GSTO2, and TMEM190 were expressed at lower levels in GC than in adjacent samples ( < 0.05). Moreover, infection decreased HUS1, GSTO2, and TMEM190 expression and . Our study identified HUS1, GSTO2, and TMEM190 as novel methylation markers for -associated GC.